XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
ALN-RSV01 Significantly Inhibits RSV Replication In Vivo
Mar 20, 2005, 11:35, Reviewed by: Dr.

"There is a significant need for novel therapies to effectively treat patients infected with RSV, a highly contagious virus that can lead to serious respiratory illnesses and hospitalization in vulnerable patient populations "

 
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has announced the presentation of in vivo efficacy data on its lead candidate RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection at The Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, Texas.

Experiments performed by researchers at Alnylam and collaborators from the University of Georgia demonstrated that a single low dose of Alnylam's lead RSV candidate, ALN-RSV01, an optimized siRNA, inhibits RSV replication both as a prophylactic and as a treatment when administered by intranasal delivery in a liquid form.

Alnylam collaborator Dr. Ralph Tripp, Ph.D., Department of Infectious Diseases, University of Georgia presented the results.

"There is a significant need for novel therapies to effectively treat patients infected with RSV, a highly contagious virus that can lead to serious respiratory illnesses and hospitalization in vulnerable patient populations," said Dr. Tripp. "Our research with Alnylam bolsters the potential for RNAi therapeutics to treat patients with RSV infections, who until now, have had few or no therapeutic options."

ALN-RSV01 specifically silences an RSV gene required for viral replication. Pre-clinical studies performed in mice demonstrated that a single low dose of ALN-RSV01 (2 mg/kg) protected against subsequent RSV infection. ALN-RSV01 was also shown to be effective in the treatment of an existing RSV infection.

Additional studies in mice demonstrated that intranasal administration of ALN-RSV01 did not activate an interferon response. Ongoing and future studies are analyzing the topical delivery of ALN-RSV01 to the lung by aerosolization through a nebulizer.

"Alnylam is rapidly progressing toward our goal of developing a safe and efficacious RNAi therapeutic for the treatment of RSV infection," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "Based on the encouraging pre-clinical data we have seen to date, we are driving ALN-RSV01 forward toward human clinical trials in the first half of 2006."

RSV is a highly contagious virus that causes repeated infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two years and is a major cause of hospitalization due to respiratory infection in children and people with compromised immune systems and others.

RSV infection typically results in cold-like symptoms but can lead to more serious respiratory illness such as croup, pneumonia, bronchiolitis, and, in extreme cases, death. RSV infection in the pediatric population accounts for greater than 100,000 hospitalizations per year in the United States.

The development of childhood asthma is also known to occur after childhood RSV infection. As a result, there is a significant need for novel therapeutics to treat patients who become infected with RSV.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes.

Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence and regulate such genes selectively through RNAi could provide a means to treat a wide range of human diseases.

The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002, as well as one of the top 10 scientific advances of 2003.
 

- The Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, Texas
 

Alnylam Pharmaceuticals, Inc.,

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi therapeutics. Alnylam is developing a pipeline of RNAi products using Direct RNAi(TM) to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi(TM) to treat a broad range of diseases, including oncology, metabolic, and autoimmune diseases. The company's global headquarters are in Cambridge, Massachusetts. For additional information, please visit the company's website.

Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us